Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA; Division of Breast Surgery, Hunan Cancer Hospital, The Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, China.
Division of Surgical Oncology, Massachusetts General Hospital, Boston, MA.
J Am Coll Surg. 2016 Jun;222(6):1149-55. doi: 10.1016/j.jamcollsurg.2016.02.016. Epub 2016 Mar 4.
When a nipple margin of a nipple-sparing mastectomy (NSM) contains malignancy, current practice includes removal of the nipple or nipple areola complex (NAC). We evaluated rates and trends of positive nipple margins, subsequent management, and oncologic outcomes.
A retrospective chart review of all NSM at our institution from 2007 to 2014 was performed. A descriptive analysis was performed of patients with positive nipple/subareolar margins.
Among 1,326 NSM, 43 of 642 (6.7%) therapeutic and 3 of 684 (0.4%) prophylactic NSM had positive nipple margins. Nipple or NAC excision was performed for 39 of 46 (85%) positive nipple margins: 20 of 39 (51%) had nipple only and 19 of 39 (49%) had the entire NAC excised. Practice evolved to remove only the nipple and retain the areola for positive nipple margins: in 2007 to 2011, 7 of 17 (41%) underwent nipple-only excision compared with 14 of 22 (64%) in 2012 to 2014. Among 39 excised nipples/NAC, 28 (72%) contained no residual malignancy, while 8 contained ductal carcinoma in situ (DCIS), 2 had invasive lobular carcinoma, and 1 had invasive ductal carcinoma. With experience, rates of positive nipple margins for therapeutic NSM decreased from 11% (17 of 160) in 2007 to 2011 to 5.4% (26 of 482) in 2012 to 2014 (p < 0.05). At 36 month median follow-up, there were no recurrences in the nipple/NAC.
Early results suggest that excision of the nipple with retention of the areola is a safe approach for management of a positive nipple margin after NSM. With experience, low rates of positive nipple margins are possible in therapeutic NSM. Overall risk of nipple/NAC recurrence after NSM remains extremely low.
当保乳乳房切除术(NSM)的乳头边缘包含恶性肿瘤时,目前的做法包括切除乳头或乳头乳晕复合体(NAC)。我们评估了阳性乳头边缘的发生率和趋势、后续处理和肿瘤学结果。
对我们机构 2007 年至 2014 年所有 NSM 的病历进行回顾性图表审查。对阳性乳头/乳晕边缘的患者进行描述性分析。
在 1326 例 NSM 中,642 例治疗性 NSM 中有 43 例(6.7%)和 684 例预防性 NSM 中有 3 例(0.4%)阳性乳头边缘。对 46 例阳性乳头边缘中的 39 例(85%)进行了乳头或 NAC 切除:20 例(51%)仅切除乳头,19 例(49%)切除整个 NAC。实践逐渐演变为仅切除乳头并保留乳晕,用于阳性乳头边缘:2007 年至 2011 年,17 例(41%)中仅切除乳头,而 2012 年至 2014 年,22 例(64%)中仅切除乳头。在切除的 39 个乳头/NAC 中,28 个(72%)未残留恶性肿瘤,8 个含有导管原位癌(DCIS),2 个有浸润性小叶癌,1 个有浸润性导管癌。随着经验的积累,治疗性 NSM 的阳性乳头边缘率从 2007 年至 2011 年的 11%(17/160)降至 2012 年至 2014 年的 5.4%(26/482)(p < 0.05)。在 36 个月的中位随访期间,乳头/NAC 无复发。
早期结果表明,在 NSM 后,切除乳头并保留乳晕是处理阳性乳头边缘的一种安全方法。随着经验的积累,治疗性 NSM 中阳性乳头边缘的低发生率是可能的。NSM 后乳头/NAC 复发的总体风险仍然极低。